Shares of METIS TECHBIO-P (07666) surged by nearly 7% at their peak during the trading session.

At the time of writing, the stock was up 4.36% to HK$13.4, with a turnover of HK$21.72 million.

Key Development

The company recently officially launched its AiProtein platform and the antibody design AI agent, AARON.

The AiProtein platform utilizes the company's proprietary innovation model that integrates in-silico, in-vitro, and intelligent agent technologies, focusing on the design of large molecules like proteins and antibodies.

As the fourth core solution powered by METIS TECHBIO-P's AI nano-delivery platform, NanoForge, AiProtein, together with AiLNP, AiRNA, and AiTEM, completes the company's end-to-end R&D cycle.

This integrated approach covers the entire process from protein design to mRNA sequence design and LNP formulation.

Platform Capabilities

The AiProtein platform supports AI-driven affinity maturation for antibody lead compounds obtained from animal immunization or library screening.

The company has specifically developed the METiS ProteinIFGT inverse folding model, which represents a significant improvement over the industry-standard ProteinMPNN model.

This innovation introduces a graph Transformer architecture into the protein inverse folding model, leading to performance gains across multiple metrics.

Building on this, the company further developed the METiS NbIFGT model for nanobodies.

This model, alongside the previously developed METiS NbBERT, acts as a dual safeguard, predicting antibody mutations from two distinct perspectives to establish a new paradigm in antibody engineering.